Adcetris-话题@MedSci

#Adcetris#

14篇内容 | 1021人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1947279, encodeId=be3b194e27954, content=<a href='/topic/show?id=94841958f6' target=_blank style='color:#2F92EE;'>#Adcetris#</a>, objectTitle=武田和Seagen呈报的ADCETRIS®联合用药数据显示，晚期霍奇金淋巴瘤患者的总生存(OS)改善有统计学意义, objectType=article, longId=728253, objectId=2392e28253a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2392e28253a7, replyNumber=0, likeNumber=66, createdTime=2023-03-22, rootId=0, userName=若水123, userId=4f272500131, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2392e28253a7, moduleTitle=武田和Seagen呈报的ADCETRIS®联合用药数据显示，晚期霍奇金淋巴瘤患者的总生存(OS)改善有统计学意义, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2392e28253a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947277, encodeId=b746194e27798, content=<a href='/topic/show?id=94841958f6' target=_blank style='color:#2F92EE;'>#Adcetris#</a>, objectTitle=欧洲监管机构批准治疗间变性大细胞淋巴瘤的靶向药物--武田抗CD30的ADC药物Adcetris, objectType=article, longId=194236, objectId=13fa194236c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=13fa194236c3, replyNumber=0, likeNumber=66, createdTime=2020-08-24, rootId=0, userName=若水123, userId=4f272500131, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=13fa194236c3, moduleTitle=欧洲监管机构批准治疗间变性大细胞淋巴瘤的靶向药物--武田抗CD30的ADC药物Adcetris, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=13fa194236c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947278, encodeId=1189194e27868, content=<a href='/topic/show?id=94841958f6' target=_blank style='color:#2F92EE;'>#Adcetris#</a>, objectTitle=喜讯！中国**靶向CD30的抗体药物偶联物ADCETRIS（brentuximab vedotin）获得批准, objectType=article, longId=194256, objectId=5af31942566d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5af31942566d, replyNumber=0, likeNumber=106, createdTime=2020-09-30, rootId=0, userName=若水123, userId=4f272500131, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5af31942566d, moduleTitle=喜讯！中国**靶向CD30的抗体药物偶联物ADCETRIS（brentuximab vedotin）获得批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5af31942566d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947276, encodeId=d931194e2762d, content=<a href='/topic/show?id=94841958f6' target=_blank style='color:#2F92EE;'>#Adcetris#</a>, objectTitle=抗体-药物偶联物：加拿大批准ADCETRIS与AVD联合化疗用于初治型晚期霍奇金淋巴瘤, objectType=article, longId=165419, objectId=c229165419d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c229165419d1, replyNumber=0, likeNumber=111, createdTime=2019-12-28, rootId=0, userName=若水123, userId=4f272500131, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c229165419d1, moduleTitle=抗体-药物偶联物：加拿大批准ADCETRIS与AVD联合化疗用于初治型晚期霍奇金淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c229165419d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947275, encodeId=7a63194e275fc, content=<a href='/topic/show?id=94841958f6' target=_blank style='color:#2F92EE;'>#Adcetris#</a>, objectTitle=FDA批准Seattle Genetics的Adcetris治疗外周T细胞淋巴瘤, objectType=article, longId=153842, objectId=37411538422c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=37411538422c, replyNumber=0, likeNumber=66, createdTime=2018-12-09, rootId=0, userName=若水123, userId=4f272500131, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=37411538422c, moduleTitle=FDA批准Seattle Genetics的Adcetris治疗外周T细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=37411538422c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947274, encodeId=85d5194e27438, content=<a href='/topic/show?id=94841958f6' target=_blank style='color:#2F92EE;'>#Adcetris#</a>, objectTitle=FDA扩大Adcetris适应症至III期或IV期经典霍奇金淋巴瘤, objectType=article, longId=133451, objectId=835d13345119, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=835d13345119, replyNumber=0, likeNumber=106, createdTime=2018-09-14, rootId=0, userName=若水123, userId=4f272500131, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=835d13345119, moduleTitle=FDA扩大Adcetris适应症至III期或IV期经典霍奇金淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=835d13345119)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947273, encodeId=33ae194e27388, content=<a href='/topic/show?id=94841958f6' target=_blank style='color:#2F92EE;'>#Adcetris#</a>, objectTitle=3期 ALCANZA临床试验表明Adcetris 可更好的改善皮肤T细胞淋巴瘤的治疗效果, objectType=article, longId=74414, objectId=5b78e4414c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5b78e4414c7, replyNumber=0, likeNumber=89, createdTime=2017-05-16, rootId=0, userName=若水123, userId=4f272500131, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5b78e4414c7, moduleTitle=3期 ALCANZA临床试验表明Adcetris 可更好的改善皮肤T细胞淋巴瘤的治疗效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5b78e4414c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947272, encodeId=295d194e272bc, content=<a href='/topic/show?id=94841958f6' target=_blank style='color:#2F92EE;'>#Adcetris#</a>, objectTitle=欧盟批准武田抗癌药Adcetris用于霍奇金淋巴瘤患者干细胞移植后的巩固治疗, objectType=article, longId=72295, objectId=f93de22957a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f93de22957a, replyNumber=0, likeNumber=69, createdTime=2017-02-25, rootId=0, userName=若水123, userId=4f272500131, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f93de22957a, moduleTitle=欧盟批准武田抗癌药Adcetris用于霍奇金淋巴瘤患者干细胞移植后的巩固治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f93de22957a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947271, encodeId=f35b194e271c1, content=<a href='/topic/show?id=94841958f6' target=_blank style='color:#2F92EE;'>#Adcetris#</a>, objectTitle=欧盟CHMP支持批准武田抗癌药Adcetris用于霍奇金淋巴瘤患者干细胞移植后的巩固治疗, objectType=article, longId=69496, objectId=dae2694960d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dae2694960d, replyNumber=0, likeNumber=82, createdTime=2017-03-30, rootId=0, userName=若水123, userId=4f272500131, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dae2694960d, moduleTitle=欧盟CHMP支持批准武田抗癌药Adcetris用于霍奇金淋巴瘤患者干细胞移植后的巩固治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dae2694960d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947270, encodeId=9bd3194e270ec, content=<a href='/topic/show?id=94841958f6' target=_blank style='color:#2F92EE;'>#Adcetris#</a>, objectTitle=ASH 2014：Adcetris可改善复发性系统性间变性大细胞淋巴瘤患者生存, objectType=article, longId=44366, objectId=115544366e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=115544366e4, replyNumber=0, likeNumber=107, createdTime=2015-04-10, rootId=0, userName=若水123, userId=4f272500131, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=115544366e4, moduleTitle=ASH 2014：Adcetris可改善复发性系统性间变性大细胞淋巴瘤患者生存, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=115544366e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947269, encodeId=0b9f194e26940, content=<a href='/topic/show?id=94841958f6' target=_blank style='color:#2F92EE;'>#Adcetris#</a>, objectTitle=ASH 2014：武田抗体偶联药物Adcetris大幅改善复发性系统间变大细胞淋巴瘤（sALCL）生存率, objectType=article, longId=43829, objectId=5fdc43829c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5fdc43829c8, replyNumber=0, likeNumber=89, createdTime=2015-08-03, rootId=0, userName=若水123, userId=4f272500131, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5fdc43829c8, moduleTitle=ASH 2014：武田抗体偶联药物Adcetris大幅改善复发性系统间变大细胞淋巴瘤（sALCL）生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5fdc43829c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947268, encodeId=7ef6194e26830, content=<a href='/topic/show?id=94841958f6' target=_blank style='color:#2F92EE;'>#Adcetris#</a>, objectTitle=武田抗体偶联药物Adcetris获日本批准, objectType=article, longId=29654, objectId=c6872965429, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c6872965429, replyNumber=0, likeNumber=134, createdTime=2014-04-27, rootId=0, userName=若水123, userId=4f272500131, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c6872965429, moduleTitle=武田抗体偶联药物Adcetris获日本批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c6872965429)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947267, encodeId=571e194e26706, content=<a href='/topic/show?id=94841958f6' target=_blank style='color:#2F92EE;'>#Adcetris#</a>, objectTitle=EMA批准抗体偶联药物Adcetris上市, objectType=article, longId=12351, objectId=d3fc1235199, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d3fc1235199, replyNumber=0, likeNumber=105, createdTime=2013-06-01, rootId=0, userName=若水123, userId=4f272500131, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d3fc1235199, moduleTitle=EMA批准抗体偶联药物Adcetris上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d3fc1235199)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947266, encodeId=4e6b194e266ea, content=<a href='/topic/show?id=94841958f6' target=_blank style='color:#2F92EE;'>#Adcetris#</a>, objectTitle=FDA：淋巴瘤治疗药Adcetris新黑框警告, objectType=article, longId=3739, objectId=31fa3e39ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=31fa3e39ec, replyNumber=0, likeNumber=61, createdTime=2012-04-26, rootId=0, userName=若水123, userId=4f272500131, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=31fa3e39ec, moduleTitle=FDA：淋巴瘤治疗药Adcetris新黑框警告, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=31fa3e39ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Adcetris

2020-05-29

若水123 (审核中...)

前往app查看评论内容

#Adcetris#

武田和Seagen呈报的ADCETRIS®联合用药数据显示，晚期霍奇金淋巴瘤患者的总生存(OS)改善有统计学意义

2023-03-22

若水123 (审核中...)

前往app查看评论内容

#Adcetris#

欧洲监管机构批准治疗间变性大细胞淋巴瘤的靶向药物--武田抗CD30的ADC药物Adcetris

2020-08-24

若水123 (审核中...)

前往app查看评论内容

#Adcetris#

喜讯！中国**靶向CD30的抗体药物偶联物ADCETRIS（brentuximab vedotin）获得批准

2020-09-30

若水123 (审核中...)

前往app查看评论内容

#Adcetris#

抗体-药物偶联物：加拿大批准ADCETRIS与AVD联合化疗用于初治型晚期霍奇金淋巴瘤

2019-12-28

若水123 (审核中...)

前往app查看评论内容

#Adcetris#

FDA批准Seattle Genetics的Adcetris治疗外周T细胞淋巴瘤

2018-12-09

若水123 (审核中...)

前往app查看评论内容

#Adcetris#

FDA扩大Adcetris适应症至III期或IV期经典霍奇金淋巴瘤

2018-09-14

若水123 (审核中...)

前往app查看评论内容

#Adcetris#

3期 ALCANZA临床试验表明Adcetris 可更好的改善皮肤T细胞淋巴瘤的治疗效果

2017-05-16

若水123 (审核中...)

前往app查看评论内容

#Adcetris#

欧盟批准武田抗癌药Adcetris用于霍奇金淋巴瘤患者干细胞移植后的巩固治疗

2017-02-25

若水123 (审核中...)

前往app查看评论内容

#Adcetris#

欧盟CHMP支持批准武田抗癌药Adcetris用于霍奇金淋巴瘤患者干细胞移植后的巩固治疗

2017-03-30

若水123 (审核中...)

前往app查看评论内容

#Adcetris#

ASH 2014：Adcetris可改善复发性系统性间变性大细胞淋巴瘤患者生存

2015-04-10

若水123 (审核中...)

前往app查看评论内容

#Adcetris#

ASH 2014：武田抗体偶联药物Adcetris大幅改善复发性系统间变大细胞淋巴瘤（sALCL）生存率

2015-08-03

若水123 (审核中...)

前往app查看评论内容

#Adcetris#

武田抗体偶联药物Adcetris获日本批准

2014-04-27

若水123 (审核中...)

前往app查看评论内容

#Adcetris#

EMA批准抗体偶联药物Adcetris上市

2013-06-01

若水123 (审核中...)

前往app查看评论内容

#Adcetris#

FDA：淋巴瘤治疗药Adcetris新黑框警告

2012-04-26

科室
- - 订阅+
  - 更多科室
工具
服务